AI Drug Discovery: De-risking Biotech Investments

Investors are flooding the AI drug discovery space with cash, drawn by the promise of faster preclinical work and huge cost savings. But sorting the real biological breakthroughs from the computational hype requires a tough, data-first diligence process. If you’re a crossover investor looking at these preclinical platforms, your main job is figuring out if an AI-designed molecule has a real shot in the clinic or if it’s just a fancy computer model.

Biological Validation is Everything

The whole point of investing in an AI drug discovery platform is its potential to speed up how we find and refine new drug candidates. Getting a drug through the traditional pipeline is a brutal grind, it’s slow, insanely expensive, and most candidates fail long before they ever see a patient, especially in preclinical and early clinical stages. AI platforms are supposed to fix this by crunching massive chemical and biological datasets to predict a molecule’s properties and build compounds with the right profile. But getting from a molecule designed on a screen to an FDA Investigational New Drug (IND) filing, let alone through Phase I and II trials, is a minefield. An AI platform’s real value comes from its ability to consistently generate molecules that actually work in messy biological systems. You can see this playing out with the leaders in the field: a company like Recursion Pharmaceuticals is building out a huge internal pipeline while also signing deals with big pharma, all based on its AI platform’s ability to move candidates forward. At the same time, Insilico Medicine has gotten a lot of press for pushing its own AI-designed drugs into the clinic, with one for idiopathic pulmonary fibrosis already hitting Phase III trials. These companies are at the forefront, and their progress shows that investors have to look past the slick algorithm and dig into the hard biological and clinical data.

Key Questions for Your Diligence on AI-Designed Assets

When you’re looking at AI drug discovery companies, you need a structured diligence plan that puts hard evidence of biological effect first. Your focus should be on a clear path to the clinic. Our framework looks at a clinical validation score, a regulatory risk rating, payer access (which signals future market strategy, even if it’s early), and published data. Here are the questions and technical benchmarks we use:

1. Clinical Validation Score: What’s the AI’s Actual Track Record?

You have to demand proof of pipeline movement. It’s that simple.

• Pipeline Depth and Quality: How many molecules have actually made it from a computer screen through in vitro and in vivo preclinical work? What’s the therapeutic focus, and does it target diseases where patients desperately need new options?
• Phase I and Phase II Trial Progression Rates: What are the company’s historical success rates for getting its AI-generated molecules through Phase I and Phase II? The Industry average Phase I and Phase II clinical trial success rates are depressingly low, so a good AI platform ought to show a real, statistically significant bump over those numbers. This data is how you assess if the platform’s predictions hold up in the real world.
• Mechanism of Action Validation: For their top drug candidates, how solid is the lab evidence backing up the predicted mechanism of action? Do they have different, independent datasets that confirm the drug is hitting its target and affecting the right pathway?
• Comparison to Traditional Methods: Can they give you hard numbers on how much faster their preclinical timeline is, or how much better their hit-to-lead success rate is, because of their AI platform versus old-school methods?

2. Regulatory Risk Rating: The FDA Pathway

The road to market is paved with regulations, so you’ve got to understand how an AI-derived drug fits into the FDA’s world.

• IND Application Readiness: What’s the plan for getting an FDA IND application filed for their AI-designed molecules? Have they already started talking to regulators? (Early conversations are a very good sign).
• Preclinical Data Package: Is the data package for their lead candidates rock solid? It needs to meet all the FDA’s requirements for toxicology, pharmacokinetics, and pharmacodynamics. Working with established preclinical CROs like Charles River Laboratories can be a big help here, since those groups have tons of experience with data generation and regulatory submissions.
• Novelty vs. Predicate: Is the AI spitting out truly new chemical structures, or is it just tweaking existing, known ones? Brand new molecules might require a much longer conversation with the FDA, while tweaks to known scaffolds could follow a more familiar path.

3. Payer Penetration Depth (Future-Proofing): Thinking About Commercial Viability Now

Even when you’re looking at a preclinical asset, smart investors are already thinking about long-term commercial potential.

• Disease Burden and Market Size: What’s the total addressable market (TAM) for the target disease and how bad is the unmet need? Does this AI-designed drug offer a clear win over what’s already out there, like better efficacy, fewer side effects, or a totally new mechanism?
• Health Economic Value Proposition: Has the company even started to think about the health economic story for its lead drugs? It might seem early, but having this foresight can shape how they run later trials and eventually price the drug.

4. Published Outcomes Data: Transparency and Peer Review

Scrutiny from the scientific community is a powerful form of validation.

• Peer-Reviewed Publications: Look for publications of their AI methods or preclinical data in top-tier journals (like Nature Reviews Drug Discovery). A company that’s transparent about how its AI performs and how its molecules are validated is showing signs of real scientific discipline.
• Patent Portfolio Size: How big and how broad is the company’s patent portfolio? You want to see patents covering the AI platform itself, the new molecules it discovers, and their uses. A dense patent portfolio is a good defense and signals a real competitive advantage. You can often get a sense of this by checking SEC filings of public biotech firms for patent portfolio details.
• Independent Validation: Has anyone else, like an academic lab or a CRO, independently confirmed the AI platform’s predictions or the effectiveness of its lead molecules?

A 5-Point Diligence Checklist for AI Biotech Pipelines

For crossover investors in biotech and healthtech, a structured process isn’t optional. Use this checklist to keep your diligence focused:

1. Proof of Progression: Demand hard data on how many AI-designed molecules got through in vitro, in vivo, and (ideally) into early human trials. Focus on what’s moved forward, not what a computer predicted.
2. Tough Biological Validation: Dig into the lab data. Does it support target engagement, the proposed mechanism, and preclinical effectiveness? A prediction is worthless without biological proof.
3. Clear Regulatory Strategy: Make sure the team understands the FDA IND process inside and out and has a plan to get through it. Look for any sign of early talks with regulators.
4. Proprietary Data and Algorithms: Figure out how deep their data moat is. Is their AI learning from unique, high-quality datasets that competitors can’t easily copy? Or are their algorithms just a rehash of stuff that’s already out there?
5. The Right Team: Look at the mix of people on the leadership team. You need computational chemists, biologists, and seasoned clinical development experts who can bridge the gap between the algorithm and the patient.

Methodology and Source Note

We built this framework by talking to biopharma computational chemists and VC partners who are actively writing checks in the AI drug discovery sector. The advice is based on their real-world experiences watching pipelines succeed and fail, dealing with regulators, and planning for commercial launch. We’re grounding these benchmarks in real-world data, pulling specific points on trial progression and patent filings from public sources like ClinicalTrials.gov, SEC filings, and scientific literature in journals such as Nature Reviews Drug Discovery articles on AI drug discovery. This framework is designed to give investors the sharp lens they need to see the true potential of AI in drug development.